The Centers for Disease Control and Prevention's Prevention for States (PfS) program funded 29 state health departments to prevent opioid overdose by implementing evidence-based prevention strategies. The objectives of this analysis were to describe the scope of activities implemented across the four PfS strategies and identify implementation challenges.
Methods
PfS recipients submitted annual progress reports (APRs) to state support staff at CDC from 2015 to 2017. APR data were used to calculate the number of required and optional activities implemented under each PfS strategy. APR data were qualitatively analyzed using a systematic content analysis approach to identify key implementation challenges.
Results
From 2015 to 2017, PfS recipients implemented 177 activities across four strategies from 2015 to 2017. Cross-cutting implementation challenges were (1) multi-sector collaboration, (2) lack of knowledge and misperceptions about opioid used disorder (OUD) among some partners and local communities and; (3) management and access to opioid data among PfS recipients.
Conclusions
PfS recipients implemented an array of prevention interventions to address the opioid overdose crisis and encountered several cross-cutting implementation challenges. Challenges and state driven solutions over the course of implementing PfS led to several lessons learned and actions that CDC enacted to continue to support and expand overdose prevention.
US Department of Health and Human Services. Opioid abuse in the United States and Department of Health and Human Services actions to address opioid-drug-related overdoses and deaths. Journal of Pain & Palliative Care. 2015;29(2):133–139.
RobinsonA, ChristensenA, BaconS. From the CDC: The Prevention for States program: preventing opioid overdose through evidence-based intervention and innovation. J Safety Res. 2019;68:231–237.
8.
FranklinG, SabelJ, JonesCM, . A comprehensive approach to address the prescription opioid epidemic in Washington State: milestones and lessons learned. Am J Public Health. 2015;105(3):463–469.
9.
RingwaltC, SanfordC, DasguptaN, . Community readiness to prevent opioid overdose. Health Promot Pract. 2018;19(5):747–755.
10.
WinstanleyEL, ZhangY, MashniR, . Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing. Drug Alcohol Depend. 2018;188:169–174.
11.
KhatiwodaP, Proeschold-BellRJ, MeadeCS, ParkLP, ProescholdbellS.Facilitators and barriers to naloxone kit use among opioid-dependent patients enrolled in medication assisted therapy clinics in North Carolina. N C Med J. 2018;79(3):149–155.
12.
MilesMB, HubermanAM, HubermanMA, HubermanM.Qualitative Data Analysis: An Expanded Sourcebook. Thousand Oaks, CA: Sage; 1994.
PardoTA, Gil-GarciaJR, BurkeGB.Building response capacity through cross-boundary information sharing: the critical role of trust. In: CunninghamM, ed. Exploiting the Knowledge Economy: Issues, Applications, Case Studies. Amsterdam: IOS Press; 2006:507–514.
15.
ButterfossFD, GoodmanRM, WandersmanA.Community coalitions for prevention and health promotion. Health Educ Res. 1993;8(3):315–330.
16.
KadushinC, LindholmM, RyanD, BrodskyA, SaxeL.Why it is so difficult to form effective community coalitions. City & Community. 2005;4(3):255–275.
17.
ButlerJC, CohenML, FriedmanCR, ScrippRM, WatzCG.Collaboration between public health and law enforcement: new paradigms and partnerships for bioterrorism planning and response. Emerg Infect Dis. 2002;8(10):1152–1156.
18.
ShepherdJP, SumnerSA. Policing and public health-strategies for collaboration. JAMA. 2017;317(15):1525–1526.
19.
SchiffDM, DrainoniM-L, Bair-MerrittM, WeinsteinZ, RosenbloomD.A police-led addiction treatment referral program in Massachusetts. N Engl J Med. 2016;375(25):2502–2503.
20.
U.S. Drug Enforcement Administration High Intensity Drug Trafficking Areas (HIDTA). Overdose Detection Mapping Application Program. Available at: http://www.odmap.org/. Accessed May 7, 2019.
MatusowH, DickmanSL, RichJD, . Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473–480.
23.
RadcliffeP, StevensA. Are drug treatment services only for ‘thieving junkie scumbags'? Drug users and the management of stigmatised identities. Soc Sci Med. 2008;67(7):1065–1073.
24.
SempleSJ, GrantI, PattersonTL.Utilization of drug treatment programs by methamphetamine users: The role of social stigma. Am J Addict. 2005;14(4):367–380.
25.
MahajanAP, SaylesJN, PatelVA, . Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS. 2008;22(Suppl 2):S67–S79.
26.
WakemanSE, Pham-KanterG, DonelanK.Attitudes, practices, and preparedness to care for patients with substance use disorder: results from a survey of general internists. Subst Abus. 2016;37(4):635–641.
27.
RollnickS, MillerWRJB, PsychotherapyC.What is motivational interviewing?Behav Cogn Psychother. 1995;23(4):325–334.
28.
RollnickS, HeatherN, BellA.Negotiating behaviour change in medical settings: the development of brief motivational interviewing. Journal of Mental Health. 1992;1(1):25–37.
29.
CarrollKM, LibbyB, SheehanJ, HylandN.Motivational interviewing to enhance treatment initiation in substance abusers: an effectiveness study. Am J Addict. 2001;10(4):335–339.
30.
BaoY, PanY, TaylorA, . Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff. 2016;35(6):1045–1051.
31.
HaegerichTM, PaulozziLJ, MannsBJ, JonesCM.What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014;145:34–47.
32.
ReismanRM, ShenoyPJ, AtherlyAJ, FlowersCR.Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse. 2009;3:41–51.
33.
DelcherC, WagenaarAC, GoldbergerBA, CookRL, Maldonado-MolinaMM.Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program. Drug Alcohol Depend. 2015;150:63–68.
34.
FinleyEP, GarciaA, RosenK, McGearyD, PughMJ, PotterJS.Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res. 2017;17(1):420.
35.
FinleyEP, SchneegansS, TamiC, . Implementing prescription drug monitoring and other clinical decision support for opioid risk mitigation in a military health care setting: a qualitative feasibility study. J Am Med Inform Assoc. 2018;25(5):515–522.
36.
PatrickSW, FryCE, JonesTF, BuntinMB.Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff. 2016;35(7):1324–1332.
